536-DC-SIGN
Homo sapiens
Protocols: Primary FL cells were used following approval from the Southampton and South West Hampshire Research Ethics Committee and Rochester, and with informed consent, in accordance with the Declaration of Helsinki. Cells were recovered from cryopreservation as previously described (6). Tumor IGHV gene sequences were identified as described (6). Where cells were incubated with DC-SIGN-Fc or DC-SIGN-HA (both R&D Systems) media was additionally supplemented with CaCl2 to a final Ca2+ concentration of 2 mM, unless otherwise stated. DC-SIGN-Fc/HA were used at 20 µg/ml and goat anti-human F(ab')2 anti-IgM (anti-IgM) and goat F(ab')2 IgG control (both Southern Biotech) were used at 10 µg/ml, unless otherwise stated. FL samples were treated with 20 μg/ml of goat F(ab')2 anti-IgM, 20 μg/ml of DC-SIGN-Fc or left untreated for 4 hours at 37°C. Total RNA was extracted using an RNeasy mini kit (Qiagen) PolyA
ENA-FIRST-PUBLIC
2020-01-31T04:02:54Z
ENA-LAST-UPDATE
2020-01-21T15:40:55Z
External Id
SAMEA6495473
INSDC center name
University of Southampton
INSDC first public
2020-01-31T04:02:54Z
INSDC last update
2020-01-21T15:40:55Z
INSDC status
public
Submitter Id
E-MTAB-8708:536-DC-SIGN
broker name
ArrayExpress
common name
human
developmental stage
adult
disease
cutaneous follicular lymphoma
individual
536
organism part
lymph node
sample name
E-MTAB-8708:536-DC-SIGN
scientific_name
Homo sapiens